These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2093 related articles for article (PubMed ID: 17038826)

  • 1. A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants.
    Samdal HH; Bakke H; Oftung F; Holst J; Haugen IL; Korsvold GE; Kristoffersen AC; Krogh G; Nord K; Rappuoli R; Berstad AK; Haneberg B
    Hum Vaccin; 2005; 1(2):85-90. PubMed ID: 17038826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
    Baz M; Samant M; Zekki H; Tribout-Jover P; Plante M; Lanteigne AM; Hamelin ME; Mallett C; Papadopoulou B; Boivin G
    Clin Vaccine Immunol; 2012 Feb; 19(2):209-18. PubMed ID: 22190392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.
    Stephenson I; Zambon MC; Rudin A; Colegate A; Podda A; Bugarini R; Del Giudice G; Minutello A; Bonnington S; Holmgren J; Mills KH; Nicholson KG
    J Virol; 2006 May; 80(10):4962-70. PubMed ID: 16641287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.
    Bakke H; Samdal HH; Holst J; Oftung F; Haugen IL; Kristoffersen AC; Haugan A; Janakova L; Korsvold GE; Krogh G; Andersen EA; Djupesland P; Holand T; Rappuoli R; Haneberg B
    Scand J Immunol; 2006 Mar; 63(3):223-31. PubMed ID: 16499576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
    Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A
    Front Immunol; 2019; 10():646. PubMed ID: 30984200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.
    Proudfoot O; Esparon S; Tang CK; Laurie K; Barr I; Pietersz G
    BMC Infect Dis; 2015 Feb; 15():101. PubMed ID: 25887952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge.
    Moriyama M; Chino S; Ichinohe T
    Vaccine; 2017 Feb; 35(7):1001-1007. PubMed ID: 28111142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination.
    Petersson P; Hedenskog M; Alves D; Brytting M; Schröder U; Linde A; Lundkvist A
    Vaccine; 2010 Sep; 28(39):6491-7. PubMed ID: 20637767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine-specific antibody secreting cells are a robust early marker of LAIV-induced B-cell response in ferrets.
    Cherukuri A; Servat E; Woo J
    Vaccine; 2012 Jan; 30(2):237-46. PubMed ID: 22080173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.
    Ren ST; Zhang XM; Sun PF; Sun LJ; Guo X; Tian T; Zhang J; Guo QY; Li X; Guo LJ; Che J; Wang B; Zhang H
    PLoS One; 2017; 12(1):e0169501. PubMed ID: 28052136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine.
    Patil HP; Murugappan S; ter Veer W; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
    J Control Release; 2014 Jan; 174():51-62. PubMed ID: 24269505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.
    Lambkin-Williams R; Gelder C; Broughton R; Mallett CP; Gilbert AS; Mann A; He D; Oxford JS; Burt D
    PLoS One; 2016; 11(12):e0163089. PubMed ID: 28005959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine.
    Das SC; Hatta M; Wilker PR; Myc A; Hamouda T; Neumann G; Baker JR; Kawaoka Y
    Vaccine; 2012 Nov; 30(48):6871-7. PubMed ID: 22989689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyanhydride nanovaccine against swine influenza virus in pigs.
    Dhakal S; Goodman J; Bondra K; Lakshmanappa YS; Hiremath J; Shyu DL; Ouyang K; Kang KI; Krakowka S; Wannemuehler MJ; Won Lee C; Narasimhan B; Renukaradhya GJ
    Vaccine; 2017 Feb; 35(8):1124-1131. PubMed ID: 28117173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.
    Treanor J; Nolan C; O'Brien D; Burt D; Lowell G; Linden J; Fries L
    Vaccine; 2006 Jan; 24(3):254-62. PubMed ID: 16129526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 105.